These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35136902)

  • 1. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study.
    Pradhan R; Patorno E; Tesfaye H; Schneeweiss S; Yin H; Franklin J; Pawar A; Santella C; Yu OHY; Renoux C; Azoulay L
    Am J Epidemiol; 2022 Jul; 191(8):1352-1367. PubMed ID: 35136902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
    Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
    Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu OHY; Azoulay L
    Diabetes Care; 2022 Oct; 45(10):2289-2298. PubMed ID: 35866685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.
    Pradhan R; Lu S; Yin H; Yu OHY; Ernst P; Suissa S; Azoulay L
    BMJ; 2022 Nov; 379():e071380. PubMed ID: 36318979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL; Mastrorilli J; Bykov K; Wexler DJ; Cervone A; Lin KJ; Patorno E; Paik JM
    Kidney Int; 2024 Mar; 105(3):618-628. PubMed ID: 38101515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    Fu EL; Wexler DJ; Cromer SJ; Bykov K; Paik JM; Patorno E
    BMJ; 2024 Jun; 385():e078483. PubMed ID: 38925801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.
    Abrahami D; Tesfaye H; Yin H; Vine S; Hicks B; Yu OHY; Campeau L; Platt RW; Schneeweiss S; Patorno E; Azoulay L
    Diabetes Care; 2022 Dec; 45(12):2907-2917. PubMed ID: 36170656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
    Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
    BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Tang H; Lu Y; Donahoo WT; Shao H; Shi L; Fonseca VA; Guo Y; Bian J; Guo J
    Ann Intern Med; 2024 Aug; 177(8):1004-1015. PubMed ID: 39008852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
    Pai YW; Chen IC; Lin JF; Chen XH; Chen HH; Chang MH; Huang JA; Lin CH
    Diabetes Obes Metab; 2024 Nov; 26(11):5420-5430. PubMed ID: 39248211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
    Pradhan R; Yu OHY; Platt RW; Azoulay L
    Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
    Simon TG; Patorno E; Schneeweiss S
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
    Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.